{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:03:00Z","timestamp":1781154180634,"version":"3.54.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002975","name":"Sumitomo Pharma Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejca.2026.116808","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:54:21Z","timestamp":1779173661000},"page":"116808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Phase 1\/2 study of a WT1 peptide-dosing emulsion in pediatric patients with recurrent\/refractory diffuse intrinsic pontine glioma, glioblastoma, or anaplastic astrocytoma"],"prefix":"10.1016","volume":"242","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1668-274X","authenticated-orcid":false,"given":"Yoshiko","family":"Hashii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Fujisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keizo","family":"Horibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Takahara-Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kikuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2033-0985","authenticated-orcid":false,"given":"Hiroshi","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9171-6585","authenticated-orcid":false,"given":"Yoshihiro","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0844-2175","authenticated-orcid":false,"given":"Haruo","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116808_bib1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/08880018.2021.1907493","article-title":"High grade gliomas in young children: the South Thames Neuro-Oncology unit experience and recent advances in molecular biology and targeted therapies","volume":"38","author":"Pearce","year":"2021","journal-title":"Pedia Hematol Oncol"},{"key":"10.1016\/j.ejca.2026.116808_bib2","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1038\/s41467-025-62260-5","article-title":"The oncolytic adenovirus Ad-TD-nsIL12 in primary or progressive pediatric IDH wild-type diffuse intrinsic pontine glioma results of two phase I clinical trials","volume":"16","author":"Qian","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2026.116808_bib3","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/neuonc\/nox107","article-title":"Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study","volume":"19","author":"Cooney","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2026.116808_bib4","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3389\/fonc.2020.01188","article-title":"Encouraging clinical evolution of a pediatric patient with relapsed diffuse midline glioma who underwent WT1-targeting immunotherapy: a case report and literature review","volume":"10","author":"Hashii","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2026.116808_bib5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jnen\/nlz021","article-title":"Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma","volume":"78","author":"Lee","year":"2019","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.ejca.2026.116808_bib6","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/j.1349-7006.2004.tb02188.x","article-title":"Overexpression of the Wilms' tumor gene W T1 in primary astrocytic tumors","volume":"95","author":"Oji","year":"2004","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2026.116808_bib7","first-page":"61","article-title":"Wilms\u2019 Tumor 1 is involved in tumorigenicity of glioblastoma by regulating cell proliferation and apoptosis","volume":"34","author":"Kijima","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2026.116808_bib8","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1242\/dev.153163","article-title":"Wilms' tumour 1 (WT1) in development, homeostasis and disease","volume":"144","author":"Hastie","year":"2017","journal-title":"Development"},{"key":"10.1016\/j.ejca.2026.116808_bib9","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.1038\/ncomms6852","article-title":"The Wilms' tumour suppressor Wt1 is a major regulator of tumour angiogenesis and progression","volume":"5","author":"Wagner","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2026.116808_bib10","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3171\/JNS-07\/09\/0586","article-title":"Wilms tumor 1 expression in malignant gliomas and correlation of +KTS isoforms with p53 status","volume":"107","author":"Clark","year":"2007","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ejca.2026.116808_bib11","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116808_bib12","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2217\/imt.10.58","article-title":"WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospects","volume":"2","author":"Oka","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ejca.2026.116808_bib13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2026.116808_bib14","doi-asserted-by":"crossref","first-page":"17ra9","DOI":"10.1126\/scitranslmed.3000349","article-title":"Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells","volume":"2","author":"Saito","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2026.116808_bib15","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00262-015-1674-8","article-title":"Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response","volume":"64","author":"Hashimoto","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2026.116808_bib16","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3171\/JNS\/2008\/108\/5\/0963","article-title":"Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme","volume":"108","author":"Izumoto","year":"2008","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ejca.2026.116808_bib17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00262-018-2274-1","article-title":"A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma","volume":"68","author":"Tsuboi","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2026.116808_bib18","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s12094-022-02946-0","article-title":"Mechanism of action of DSP-7888 (adegramotide\/nelatimotide) Emulsion, a peptide-based therapeutic cancer vaccine with the potential to turn up the heat on non-immunoreactive tumors","volume":"25","author":"Suginobe","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ejca.2026.116808_bib19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11523-021-00813-6","article-title":"Multicenter, open-label, phase I study of DSP-7888 dosing emulsion in patients with advanced malignancies","volume":"16","author":"Spira","year":"2021","journal-title":"Target Oncol"},{"key":"10.1016\/j.ejca.2026.116808_bib20","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/cas.15245","article-title":"Phase 1\/2 study evaluating the safety and efficacy of DSP-7888 dosing emulsion in myelodysplastic syndromes","volume":"113","author":"Ueda","year":"2022","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2026.116808_bib21","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/jmri.26171","article-title":"Pseudoprogression of brain tumors","volume":"48","author":"Thust","year":"2018","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.ejca.2026.116808_bib22","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8374328","article-title":"Altered Intracellular ATP Production by Activated CD4+ T-Cells in Very Preterm Infants","volume":"2016","author":"Aquilano","year":"2016","journal-title":"J Immunol Res"},{"key":"10.1016\/j.ejca.2026.116808_bib23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0022-3476(05)80430-5","article-title":"Age-related changes in human blood lymphocyte subpopulations","volume":"120","author":"Erkeller-Yuksel","year":"1992","journal-title":"J Pedia"},{"key":"10.1016\/j.ejca.2026.116808_bib24","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s11912-014-0436-7","article-title":"Pediatric brainstem gliomas: new understanding leads to potential new treatments for two very different tumors","volume":"17","author":"Green","year":"2015","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ejca.2026.116808_bib25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/CJI.0b013e3181fb65b9","article-title":"Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer","volume":"34","author":"Kaida","year":"2011","journal-title":"J Immunother"},{"key":"10.1016\/j.ejca.2026.116808_bib26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/jjco\/hyl005","article-title":"A phase I\/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data","volume":"36","author":"Morita","year":"2006","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116808_bib27","first-page":"4779","article-title":"Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy","volume":"29","author":"Ohno","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2026.116808_bib28","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1592\/phco.27.11.1512","article-title":"Diagnosis and treatment of adrenal insufficiency in the critically ill patient","volume":"27","author":"Asare","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejca.2026.116808_bib29","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/pbc.22522","article-title":"WT1 peptide immunotherapy for cancer in children and young adults","volume":"55","author":"Hashii","year":"2010","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.ejca.2026.116808_bib30","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/sj.leu.2404380","article-title":"Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein","volume":"20","author":"Pinilla-Ibarz","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2026.116808_bib31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s002510050018","article-title":"Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product","volume":"51","author":"Oka","year":"2000","journal-title":"Immunogenetics"},{"key":"10.1016\/j.ejca.2026.116808_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01707-3","article-title":"A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies","volume":"11","author":"Fu","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2026.116808_bib33","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s00262-002-0328-9","article-title":"Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues","volume":"51","author":"Tsuboi","year":"2002","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2026.116808_bib34","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/neuonc\/nou091","article-title":"Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma","volume":"16","author":"Bartels","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2026.116808_bib35","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116808_bib36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11060-017-2701-8","article-title":"Survival outcomes in pediatric recurrent high-grade glioma: results of a 20-year systematic review and meta-analysis","volume":"137","author":"Kline","year":"2018","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ejca.2026.116808_bib37","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4(+) T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ejca.2026.116808_bib38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00262-021-02954-z","article-title":"Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy","volume":"71","author":"Yokota","year":"2022","journal-title":"Cancer Immunol Immunother"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:54:49Z","timestamp":1781153689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926005897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":38,"alternative-id":["S0959804926005897"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116808","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1\/2 study of a WT1 peptide-dosing emulsion in pediatric patients with recurrent\/refractory diffuse intrinsic pontine glioma, glioblastoma, or anaplastic astrocytoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116808","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116808"}}